Factors Affecting Timing of Hypothyroidism Following Radioactive Iodine Therapy Patients With Graves Disease

Launched by ASSIUT UNIVERSITY · Dec 7, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the factors that may influence how quickly some patients develop hypothyroidism (an underactive thyroid) after receiving radioactive iodine therapy for Graves' disease, a condition that causes an overactive thyroid. Researchers want to understand why some patients experience early symptoms of hypothyroidism following this treatment, which is often used to manage Graves' disease.

To be eligible for this study, participants should be adults aged 18 to 80 who have been treated with radioactive iodine for Graves' disease at least a year ago. They should also have specific thyroid hormone levels, including low thyroid-stimulating hormone (TSH) and high levels of other thyroid hormones. Participants will undergo assessments and follow-ups for about six months. The information gathered will help doctors better understand how to manage thyroid health after treatment for Graves' disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Graves' disease patients after one year of RAI therapy .
• • 2. Suppressed serum thyrotropin (TSH) \<0.55 µU/ml , elevated serum free triiodothyronine (FT3) \> 6.5 pmol/L , free thyroxin FT4 \>22.7 pmol/L .
• Exclusion Criteria:
• • 1. Patients with other causes of hyperthyroidism , such as toxic multinodular goiter and single toxic adenoma
• • 2. Thyroid cancer
• • 3. Recurrent GD
• • 4. Previous Thyroid surgery
• • 5. Patients can't complete the follow -up within 6 months.

Trial Officials